News
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
5h
MarketBeat on MSNSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...
Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.
A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...
The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...
The long-short ratio in the perpetual futures market has fallen to 0.9298, indicating bearish sentiment among traders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results